MicroPort Attends EuroPCR 2015

Paris, France – 21 May, 2015 – Shanghai MicroPort Medical (Group) Co ("MicroPort") recently attended EuroPCR 2015, a world leading course in interventional medicine that was held in Paris, to present our in-development bioresorbable scaffold and to promote our Firehawk® to more patients around the world.
 
On May 19, a symposium was held to discuss innovative stents, co-chaired by Professor Runlin Gao, Chief Expert of Cardiology Department with the Fuwai Hospital and President of China Interventional Therapeutics ("CIT"), and C.K. Naber, an internationally renowned expert. In the symposium, Vice President of Fuwai Hospital Yuejin Yang introduced Firehawk®'s major features and the latest clinical outcome of Target trials. He shared his experience in using MicroPort products and spoke highly of the devices. Professor Yang also announced that MicroPort planned to launch a large-scale, randomized trial - TARGET ALL Comer - in Europe.
 
Meanwhile, Dr. Virmani, who serves as the President and Medical Director of CVPath Institute, introduced MicroPort's in-development bioresorbable scaffold to people in attendance, the first time for the new stent to appear in an international event. The bioresorbable scaffold features cutting-edge technologies including reduced scaffold thickness and Target Eluting technology with abluminal coating. Dr. Virmani released its six-month animal experimental results, which was positively received by the audience.
 
On May 21, the congress hosted a special session themed "Treating Left Main Complex Lesions with Percutaneous Coronary Intervention ("PCI")," co-chaired by Professor Runlin Gao and a French expert Dr. Morice. In the session, a surgery treating left main complex lesions with Firehawk® was broadcasted. The surgery was done by Professor Shaoliang Chen, a senior cardiologist of Nanjing First Hospital, and was well received by the attendees. Specifically, the patient was diagnosed with highly complex lesions involving LM, LAD and LCX, and calcification pervaded LCX. Syntax score was 31 and Syntax score II predicted that the mortality rate of applying PCI was lower than that of CABG. FFR showed 0.73, which indicated significant ischemia. Therefore, Professor Chen decided to predilate and then to implant two Firehawk® stents in LCX and LAD by using DK-Crush technique. IVUS and angiography showed TIMI flow 3 and the procedure was done successfully. The surgery once again proved Firehawk®'s safety and efficacy.
 
In the EuroPCR 2015, MicroPort was present with a booth which attracted much attention from surgeons and industry experts. Many of them showed interest in our products and had active interaction with our employees.